Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report

Gerald Batist, Joo Yeoun Pa


Compassionate use of Saltikva was sought for a patient with stage 4, metastatic pancreatic cancer. Approval was granted for an n=1 multiple dose (every 2 week) trial with concomitant FOLFIRINOX. Now, at 15 months, this patient has not experienced any toxicity to Saltikva, continues therapy, has normalized CA19-9 levels, maintained her immunologic cell populations despite cytotoxic chemotherapy, demonstrated a strong NK cell response, and has a radiologic regression of metastatic tumor burden with a complete absence of tumor activity by PET scan. 

Relevant Publications in Clinical Oncology: Case Reports